DuPont (DD)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-08
$139.60-1.02%
Close 2026-07-07 · 1-day change
Reading DD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DD free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-08
Reading DD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DD free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
DuPont's growth depends on achieving 4% organic growth in 2026. The company recently beat earnings expectations by 14.6%, showing steady performance. It trades at 44× P/E, which is 1.9× the peer median of 24. The market is pricing in more growth than the company can deliver. If DuPont cuts guidance after raising it, that could hurt its credibility. Peer multiples imply a price about 204% below where it trades. This read is provisional.
Trailing returns as of 2026-07-07. DD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering DD (as of Jul 2026).
Based on 3 Wall Street analysts offering 12-month price targets for DD in the last 4 months.
A consensus fair price across 14 valuation methods, at three horizons. Current price $139.60. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Threatens: Raise full year 2026 EPS guidance
Concerns about Q3 guidance may impact EPS expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $139.60
The last 12 months of price, then the range of analyst 12-month targets from today’s $139.60.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Achieve 4% organic growth in 2026
New product launch supports growth in targeted markets.
Advances: Align 2026 guidance with medium-term targets
Achieving renewable electricity aligns with sustainability goals.
Advances: Achieve 4% organic growth in 2026
New product launch supports organic growth objectives.
Advances: Align 2026 guidance with medium-term targets
Certification enhances product credibility and aligns with growth targets.